Orai3 is a predictive marker of metastasis and survival in resectable lung adenocarcinoma.

Nazim Benzerdjeb,Henri Sevestre,Halima Ouadid-Ahidouch,Ahmed Ahidouch

doi:10.18632/oncotarget.13149

Abstract

Orai3 channel has emerged as important player in malignant transformation. Indeed, its expression is increased in cancer and favors cell proliferation and survival by permitting calcium influx. In this study, Orai3 was overexpressed in lung adenocarcinoma as compared to their matched non-tumour samples and was associated with tumoural aggressiveness. Moreover, its expression was associated with estrogen receptor alpha (ERα) expression and visceral pleural invasion in multivariate analysis. Furthermore, both the overall survival (OS) median and the metastasis free survival (MFS) median of tumors with high Orai3 expression were lower than in low Orai3 expression regardless of cancer stage (35.01 months vs. 51.11 months for OS and 46.01 months vs. 62.04 months for MFS). In conclusion, Orai3 protein level constitutes an independent prognostic marker in lung adenocarcinoma, and a novel prognostic marker that could help selecting the patients with worst prognosis to be treated with adjuvant chemotherapy in resectable stage.

Highlights

Lung cancer, adenocarcinoma, is the leading cause of cancer deaths worldwide [1] and the most common histologic type of lung cancer [2]
We confirmed that Orai3 is overexpressed in lung adenocarcinomas (Figure 1A)
Among the 200 cases of tumour tissues matched with non-tumour tissues tested, the score of Orai3 staining in tumour tissues was higher than in matched non-tumour ones

Summary

Introduction

Adenocarcinoma, is the leading cause of cancer deaths worldwide [1] and the most common histologic type of lung cancer [2]. Lung adenocarcinoma is known to be a very heterogeneous tumour, with over 90% of resected tumours [3] For this reason, the accuracy of patient prognosis prediction of the international staging system is still insufficient with recurrence rate after radical surgery around 40% of early stage patients [4]. The predominant histologic pattern: low (lepidic), intermediate (papillary, acinar) and high risk (solid, micropapillary), constitutes a predictive factor for recurrence in resectable stage lung adenocarcinoma [4]. Others immunohistochemical biomarkers, such as estrogen receptor alpha expression (ERα) expression, are associated with a poor prognosis in lung adenocarcinoma [9, 10]. Few studies have discussed a biomarker involved in calcium metabolism

Methods

Results

Conclusion